Marius Pharmaceuticals


Marius Pharmaceuticals is dedicated to revolutionizing hormone health and metabolic vitality through science-backed therapies, focusing on addressing testosterone deficiency in men and women. Their mission is to improve lives by providing innovative, safe, and effective treatments, including the proprietary oral testosterone therapy KYZATREX. They aim to lead in research, education, and patient care in the field of hormone and metabolic health.

Industries

biopharma
health-care
medical
mens
pharmaceutical

Nr. of Employees

small (1-50)

Marius Pharmaceuticals


Patents

Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols

US-12295961-B2

View Details

Emulsion formulations

US-11617758-B2

View Details

Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols

US-11590146-B2

View Details

Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols

US-10576090-B2

View Details

Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols

US-10576089-B2

View Details

Products

Oral testosterone undecanoate softgel formulation

An oral softgel testosterone undecanoate formulation designed for lymphatic absorption to provide systemic testosterone replacement while reducing first-pass hepatic exposure.


Services

Collaborative design and sponsorship of multi-center clinical trials, investigator-led pilot studies, and PK/safety studies with academic and clinical investigators.

Establish and manage partnerships with clinic networks, telehealth and digital wellness providers, and health systems to expand product availability and support patient access programs.

Design and operationalize global early access and compassionate use programs via third-party service partners to provide therapy access prior to or shortly after approval.

Develop and run disease awareness campaigns and digital educational resources to inform patients and clinicians about diagnosis, treatment options, and monitoring requirements.

Advisory support for regulatory filings, labeling discussions, and patent/IP management, including preparation for regulatory listings and support for market entry.

Coordinate partnerships with academic medical centers to support design and conduct of translational and interventional research programs in perioperative and critical care settings.

Expertise Areas

  • Testosterone replacement therapy development
  • Clinical trial management and execution
  • Formulation development for lymphatic-mediated oral delivery
  • Regulatory affairs and submissions
  • Show More (6)

Key Technologies

  • Lymphatic-mediated oral delivery
  • Softgel capsule formulation
  • Lipid/phytosterol-based excipient systems for oral bioavailability
  • Ambulatory blood pressure monitoring (ABPM)
  • Show More (6)

News & Updates

A study showing minimal increases in ambulatory blood pressure following 120 days on KYZATREX, with no clinical significance in normotensive men.

Partnership to expand access to KYZATREX through affiliated urologic in-office dispensaries.

An awareness initiative to educate men about testosterone deficiency and treatment options.

The company received its sixth U.S. patent for KYZATREX, extending coverage to 2040.

Sponsoring the event focused on XY Chromosome Variations, including Klinefelter’s Syndrome, highlighting KYZATREX as a treatment option.

Launching a new website and introducing the Longevity and Endocrinology Advisory Boards with leading experts.

View All News

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.